Investors are increasingly wary of the rare-disease space, spooked by a regulatory shift.

When GSK’s new CEO Luke Miels told investors last month that “smart business development” is a key pillar for his strategy, he wasn’t lying. | Like Merck & Co.’s PAH drug Winrevair—which brought in $1 ...

GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from ...

Transformative Biotech LLC, a Boulder-based company working to develop faster molecular tests for diseases such as COVID-19 and cancer, has appointed Mark Kelleher as executive vice president of ...

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending into 2028. Read XFOR stock update.

This biotech powerhouse could maintain its strength for the long term.

Industry leaders met in San Diego to debate whether U.S. biotechs are losing ground to China. Meanwhile, across the Pacific, ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Eli Casdin, Casdin Capital CEO, joins 'Closing Bell' to discuss the biotech sector, the stocks Casdin favors and much more.

As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...

Come to the Biotech Career & Futures Fair, where representatives of top biotech and biopharmaceutical companies will discuss their current and future job openings. The event is open to all Wake Tech ...